Skip to main content

Is My Product Recalled?

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Scan How It Works Saved Get Alerts

Menu

Search All Recalls Latest Recalls Scan Barcode Get Alerts

Categories

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Resources

How Recalls Work FAQ Recall Classifications Statistics & Trends About

Your Recalls

Loading...

Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

Search Product Recalls

Try:····

Filters

Category

All Categories Food Medication Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Time Period

All Time Last 30 Days Last 90 Days Last Year

State

Severity

All Severities Class I (High Risk)Class II (Moderate)Class III (Low)

Source

All Sources FDA CPSC USDA NHTSA

Status

Include terminated recalls

Clear all filters

Showing 13741–13760 of 14362 results

Sort:

Newest first Oldest first

Itraconazole Eye Ointment (Clinical Specialties) – Sterility Concerns (2013)

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Class IIModerate

FDAMar 20, 2013FL, GA, SC• Clinical Specialties Compounding Pharmacy

Test Cyp-Lidocaine Injection (Clinical Specialties) – Sterility Concerns (2013)

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Class IIModerate

FDAMar 20, 2013FL, GA, SC• Clinical Specialties Compounding Pharmacy

Tizanidine Tablets (Dr. Reddy's) – Labeling Issue (2013)

Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.

Class IIILow

FDAMar 19, 2013Nationwide• Dr. Reddy'S Laboratories

Disulfiram Tablets (Teva) – Missing Cotton Coil (2013)

CGMP Deviation; cotton coil is missing in some packaged bottles

FDAMar 19, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Piperacillin-Tazobactam Injection (Apotex) – Crystallization Risk (2013)

Crystallization: Potential to exhibit precipitation/crystallization in IV bag or IV line upon reconstitution.

FDAMar 18, 2013Nationwide• Apotex Corp.

Donnatal Extentabs (West-ward) – Incorrect Labeling (2013)

Labeling: Incorrect or Missing Lot and/or Exp Date: Bottled product is labeled with an expiration date of Apr 2015. The correct expiration is Apr 2013.

Class IIModerate

FDAMar 18, 2013Nationwide• West-ward Pharmaceutical Corp.

Camila Tablets (Physicians Total Care) – Impurity Detected (2013)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

FDAMar 18, 2013MO• Physicians Total Care, Inc.

Ferrous Sulfate Tablets (Magno Humphries) – plastic contamination (2013)

The firm found minute pieces of blue material identified by their raw material supplier as polypropylene, a relatively inert plastic.

FDAMar 18, 2013Nationwide• Magno Humphries Inc

Oxcarbazepine Tablets (Boehringer Ingelheim) – Subpotent Drug (2013)

SubPotent Drug: The firm discovered out of specification results for assay and the extended investigation revealed the potential for lower weight tablets.

FDAMar 18, 2013Nationwide• Boehringer Ingelheim Roxane Inc

Ethambutol Tablets (West-ward) – Subpotent Medication (2013)

Subpotent Drug: Out Of Specification results for assay at the stability time-point of 24 months.

Class IIModerate

FDAMar 18, 2013Nationwide• West-ward Pharmaceutical Corp.

Jolessa Tablets (Teva) – Impurity Specification Failure (2013)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

FDAMar 15, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Camila Tablets (Teva) – Impurity Specification Failure (2013)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

FDAMar 15, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Lessina Tablets (Teva) – Impurity Specification Failure (2013)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

FDAMar 15, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Balziva Tablets (Teva) – Impurity Specification Failure (2013)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

FDAMar 15, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Errin Tablets (Teva) – Impurity Specification Failure (2013)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

FDAMar 15, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Junel Fe Tablets (Teva) – Impurity Specification Failure (2013)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

FDAMar 15, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Seasonale Tablets (Teva) – Impurity Specification Failure (2013)

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing

FDAMar 14, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Compounded Products (Med Prep) – Sterility Concern (2013)

Lack of Assurance of Sterility; potential for mold contamination

Class IIModerate

FDAMar 14, 2013Nationwide• Med Prep Consulting, Inc.

Camrese Tablets (Teva) – Impurity Specification Failure (2013)

Failed Impurity/Degradation Specifications; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing

FDAMar 14, 2013Nationwide• Teva Pharmaceuticals USA, Inc.

Combat Powder (Integrity Nutraceuticals) – packaging contamination (2013)

One lot of each product may have extraneous materials due to a problem on the packing line.

Class IIModerate

FDAMar 14, 2013AR, CA, CO +11 more• F.H.G Corporation dba Integrity Nutraceuticals

1...686 687688689 690...719

Page 688 of 719Next